Vectura Group PLC (LON:VEC) insider Andrew Derodra purchased 135 shares of the stock in a transaction on Friday, August 4th. The shares were purchased at an average price of GBX 111 ($1.45) per share, with a total value of £149.85 ($195.14).
Andrew Derodra also recently made the following trade(s):
- On Tuesday, June 6th, Andrew Derodra purchased 135 shares of Vectura Group PLC stock. The shares were purchased at an average price of GBX 111 ($1.45) per share, with a total value of £149.85 ($195.14).
Shares of Vectura Group PLC (VEC) opened at 111.50 on Thursday. Vectura Group PLC has a 52-week low of GBX 109.50 and a 52-week high of GBX 166.97. The company has a 50-day moving average of GBX 113.16 and a 200 day moving average of GBX 131.99. The stock’s market cap is GBX 755.58 million.
COPYRIGHT VIOLATION NOTICE: “Andrew Derodra Buys 135 Shares of Vectura Group PLC (LON:VEC) Stock” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://sportsperspectives.com/2017/08/10/andrew-derodra-buys-135-shares-of-vectura-group-plc-lonvec-stock.html.
VEC has been the subject of several analyst reports. N+1 Singer cut shares of Vectura Group PLC to a “sell” rating in a report on Monday, April 24th. Royal Bank Of Canada cut shares of Vectura Group PLC to an “underperform” rating in a report on Tuesday, April 25th. Numis Securities Ltd reiterated a “buy” rating and set a GBX 225 ($2.93) price target on shares of Vectura Group PLC in a report on Tuesday, April 25th. J P Morgan Chase & Co lowered their price target on shares of Vectura Group PLC from GBX 240 ($3.13) to GBX 210 ($2.73) and set an “overweight” rating for the company in a report on Friday, May 12th. Finally, Peel Hunt reiterated a “hold” rating and set a GBX 160 ($2.08) price target on shares of Vectura Group PLC in a report on Friday, June 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of GBX 210.13 ($2.74).
About Vectura Group PLC
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.